Beyond Air, Inc.

As of June 24, 2024, Beyond Air, Inc. is rated as risky due to overvaluation and significant financial distress, reflected in poor key ratios and a year-to-date stock performance decline of 68.06%, contrasting sharply with the S&P 500's 12.22% gain.

As of June 24, 2024, Beyond Air, Inc. is rated as "risky" and overvalued, with key financial ratios indicating distress, a year-to-date return of -47.11%, and underperformance compared to its peers and the S&P 500.

As of June 13, 2025, the trend is mildly bearish due to daily moving averages and Bollinger Bands indicating bearish momentum, despite some mildly bullish signals from MACD and KST, with overall sentiment weakened by underperformance against the S&P 500 and bearish indications from RSI, Dow Theory, and OBV.

As of March 2022, the management team of Beyond Air, Inc. includes Steven Lisi (Chairman and CEO), Amir Avniel (President and COO), and independent directors Ron Bentsur, Robert Carey, William Forbes, Yoori Lee, and Erick Lucera. They are responsible for the company's strategic direction and operations.

Beyond Air, Inc. is a medical device company developing a nitric oxide generator and delivery system for the Pharmaceuticals & Biotechnology industry. As of December 2024, it reported net sales of $1 million and a net loss of $13 million, with a market cap of $24.62 million.

As of Jun 18, Beyond Air, Inc. has a market capitalization of 24.62 million and reported net sales of 3.02 million with a net profit loss of 54.97 million over the latest four quarters.